New Spinoff Means to Rev Up Omics genengnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from genengnews.com Daily Mail and Mail on Sunday newspapers.
Better Outfitted and Screened Viral Vectors Are Safer and More Effective Better Outfitted and Screened Viral Vectors Are Safer and More Effective
Adeno-associated virus (AAV) vectors are the leading vectors for gene delivery. Two AAV-based gene therapies have been approved by the U.S. Food and Drug administration, and dozens more are in clinical trials. However, AAV vectors pose challenges including costly manufacture, high percentages of empty capsids, and safety issues associated with high-dose regimens. To address this last challenge, developers are working to improve the impact of each AAV particle so that fewer particles will be required. [Dr. Microbe/Getty Images]
Sanofi partners with SIRION to improve AAV capsids for gene therapy treatments
24th February 2021
SIRION Biotech has signed a license and collaboration with Sanofi to develop improved adeno-associated virus capsids for gene therapy treatments for disorders affecting major human organs.
Sanofi, working with SIRION Biotech and professor Dirk Grimm, a scientist in the field of AAV biology and application working at Heidelberg University Hospital in Germany, will combine their technology platforms to create next-generation AAV vectors.
As part of the collaboration, the partners will aim to develop new and modified AAV capsids with a safe product profile and improved specificity, with higher gene delivery efficiency.
(Sanofi)
French Big Pharma Sanofi is teaming up with Germany’s Sirion Biotech for its viral-vector-based gene delivery tech.
The pair will work together on developing improved tissue-selective adeno-associated virus (AAV) vectors to tee up better gene therapy treatments. Targets have not yet been specifically mentioned, simply for “disorders affecting major human organs.” Financials of the deal were not made public.
This comes two years after Sirion penned a similar pact with Denali Therapeutics, with other partners including Acucela and Orchard Therapeutics.
Sanofi will work with Sirion and the German company’s partner at Heidelberg University Hospital, Dirk Grimm, to develop new and modified AAV capsids. The overall goal is to make safer, better gene therapies.
Home / Top News / Mustang Bio Provides Updates on its Lentiviral Gene Therapies for the Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”)
Mustang Bio Provides Updates on its Lentiviral Gene Therapies for the Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”)
FDA removes clinical hold for pivotal Phase 2 MB-107 clinical trial
Company plans to enroll first patient in MB-107 pivotal trial in the second quarter of 2021
Clinical outcomes in investigator-IND XSCID trials continue to show compelling efficacy
WORCESTER, Mass., Feb. 02, 2021 (GLOBE NEWSWIRE) Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today provided updates on MB-107 and MB-207, its lentiviral gene therapies for the treatment of X-linked severe combined immunodeficien